Ignite Creation Date:
2024-05-05 @ 4:48 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00318539
Status:
COMPLETED
Last Update Posted:
2011-01-21
First Post:
2006-04-25
Brief Title:
Addition of Quetiapine in Obsessive Compulsive Disorder - Westenberg Study
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
Quetiapine Augmentation to SRIs for Patients With Obsessive Compulsive Disorder a Double-blind Placebo-controlled Study
Status:
COMPLETED
Status Verified Date:
2011-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Quetiapine Seroquel an atypical antipsychotic registered for use in schizophrenia which has a very low propensity of extrapyramidal and endocrine side-effects has also been studied as an adjunct in OCD In an open trial ten patients with OCD who had not responded to at least three previous treatments with a SRI at maximum dose and duration were assigned to receive quetiapine in addition to a SRI for 8 weeks Given the efficacy of quetiapine in treatment resistant patients and given its rapid onset of action 4-6 weeks it is postulated that the combination of a low dose atypical antipsychotic and a standard dosage of an SRI as a treatment for patients with OCD might increase the number of responders as well as the effect size
PLEASE NOTE Seroquel SR and Seroquel XR refer to the same formulation The SR designation was changed to XR after consultation with FDA
PLEASE NOTE Seroquel SR and Seroquel XR refer to the same formulation The SR designation was changed to XR after consultation with FDA
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None